Pricing Log in Create free account

Galectin Therapeutics Inc. (GALT) vs ARS Pharmaceuticals, Inc. (SPRY)

Galectin Therapeutics Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Galectin Therapeutics Inc. and ARS Pharmaceuticals, Inc. are of similar size ($404.8M and $374.2M). Galectin Therapeutics Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 13 metrics below, Galectin Therapeutics Inc. leads on 10 and ARS Pharmaceuticals, Inc. on 3.

Valuation

Metric GALT SPRY Biotechnology median
P/E n/m n/m 8.50
P/S n/m 3.37 9.71
P/B n/m 31.51 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 3.61 9.21
Earnings yield (11.91%) (54.91%) (33.15%)
Free cash flow yield (6.68%) (53.80%) (25.50%)

Profitability

Metric GALT SPRY Biotechnology median
Gross margin 0.00% 71.37% 65.16%
Operating margin 0.00% (184.96%) 0.00%
Net margin 0.00% (184.26%) 0.00%
Free cash flow margin 0.00% (167.97%) 0.00%
Return on equity 21.69% (210.37%) (56.36%)
Return on assets (184.22%) (76.54%) (48.04%)
Return on invested capital 0.00% (335.65%) 0.00%

Growth

Metric GALT SPRY Biotechnology median
Revenue growth (TTM) — 4.08% 6.02%
EPS growth (last fiscal year) 36.84% (2,275.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GALT SPRY Biotechnology median
Debt to equity (0.76) 13.72 0.00
Current ratio 0.10 3.48 4.72
Net debt to EBITDA (5.79) 0.42 0.96

Dividend

Metric GALT SPRY Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GALT SPRY Biotechnology median
Market cap 374.15m 404.75m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack